Cargando…
Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery
BACKGROUND: Some oligometastatic lung cancer patients, after induction systemic chemotherapy or tyrosine kinases inhibitor treatment, followed by aggressive radical consolidative treatment, have improved overall survival. Unfortunately, clinical criteria cannot assess such patients. CASE PRESENTATIO...
Autores principales: | Tsai, Ping-Chung, Yeh, Yi-Chen, Huang, Chien-Sheng, Chiu, Chao-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851272/ https://www.ncbi.nlm.nih.gov/pubmed/31720896 http://dx.doi.org/10.1186/s40792-019-0741-3 |
Ejemplares similares
-
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017) -
Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”
por: Gion, Maria, et al.
Publicado: (2022) -
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022) -
Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-based Review
por: Freedman, Gary M., et al.
Publicado: (2023) -
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)